SYK Stryker Corporation - Fundamental Analysis
NEUTRAL
SYK Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Medical Devices
Current Price
$362.22
Analyst Target
$428.96
+18.4% Upside
52W High
$406.19
52W Low
$329.16
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Stryker Corporation trades at a premium valuation with solid long-term fundamentals and industry-leading margins, but near-term earnings growth has decelerated and recent insider selling raises caution. While the company maintains strong profitability and a resilient balance sheet, its P/E of 47.6x and forward P/E of 26.77x reflect lofty expectations not fully supported by current 2.8% YoY earnings growth. Price performance has lagged over the past year (-4.6%) despite robust 3Y and 5Y returns, and while analysts maintain a 'buy' rating with a $428.96 target implying 18% upside, recent earnings misses and insider outflows temper conviction. Relative to peers like DHR and TMO, SYK shows stronger margin discipline but weaker growth momentum, positioning it as a quality stock priced for perfection in a sector facing mixed macro headwinds.
Key Strengths
Gross margin of 65.05% is best-in-class among medical device peers, reflecting pricing power and operational efficiency
Operating margin of 22.27% exceeds sector average and peer group, including DHR (margin not provided but implied lower) and TMO (implied ~15%)
Revenue growth of 10.2% YoY outpaces peer median and aligns with sector innovation tailwinds in robotics and surgical tech
Strong ROA of 7.50% and ROE of 14.04% indicate efficient asset utilization and solid returns despite conservative leverage
Analyst target price of $428.96 implies 18.4% upside, supported by 27 analysts maintaining a 'buy' consensus
Key Risks
Earnings growth of 2.8% YoY lags revenue growth, signaling margin compression or cost pressures despite high operating leverage
P/E of 47.60x is significantly above sector average (43.86x) and peers like DHR (45.42x), AMGN (26.02x), and TMO (33.45x), increasing vulnerability to multiple contraction
Recent insider selling totaling $260.79M over the past six months, including large director sales, suggests lack of confidence at current valuation
Q/Q EPS growth of only +1.9% and two earnings misses in the last four quarters (including a -25.8% surprise in Q1 2025) indicate execution volatility
Forward P/E of 26.77x requires sustained double-digit growth to justify; any slowdown could pressure shares given limited near-term catalysts
AI Fair Value Estimate
Based on comprehensive analysis
$385.0
+6.3% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare SYK against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations